Rosetta Genomics Reports Second Quarter 2008 Financi...(ch of the first diagnostic testsapplying...)

Date:8/19/2008

ch of the first diagnostic tests applying Rosetta Genomics' technology in 2008, and Rosetta's expected cash usage in 2008 constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the continued uncertainty in the credit and capital markets that may result in these markets deteriorating further or Rosetta experiencing additional ratings downgrades on any ongoing investments in its portfolio (including on ARS); changes in the accounting treatment and final results for 2007 resulting from final third party valuations of the ARS; the current lack of liquidity of the ARS having a impact on Rosetta's liquidity, cash flow or its ability to fund its operations; other changes in general economic and business conditions; Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products and services; the successful development of diagnostic and therapeutic products applying Rosetta's technology, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals for products, as may be required under applicable laws; competition from others using technology similar to Rosetta's and others devel
'/>"/>

SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
2. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
3. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
4. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
5. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
6. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
7. /C O R R E C T I O N -- Rosetta Genomics Ltd/
8. Rosetta Genomics Reports First Quarter 2008 Financial Results
9. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference